ArticleBMC pulmonary medicine2025

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.

Jing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.